Navigation Links
Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
Date:4/23/2009

ent to $736 million versus $749 million for the first quarter of 2008. The decline in first quarter 2009 sales reflects the negative impact of changes in foreign exchange, which aggregated approximately $69 million. Excluding the impact of foreign exchange, total product sales decreased 7 percent and international product sales increased 7 percent.

Worldwide sales of Aranesp(R) (darbepoetin alfa) decreased 18 percent to $626 million in the first quarter of 2009 versus $761 million during the first quarter of 2008. In the U.S., Aranesp sales decreased 28 percent to $292 million in the first quarter of 2009 versus $405 million in the first quarter of 2008. U.S. sales in the first quarter of 2009 were negatively impacted by $12 million from changes in accounting estimates related to accruals for sales incentives for sales in prior periods. In addition, sales in the first quarter of 2008 were positively impacted by $22 million due to a change in the accounting estimate related to product sales return reserves. Excluding the impact of these changes in accounting estimates, U.S. sales of Aranesp declined 21 percent in the first quarter of 2009. The decrease was principally driven by a decline in demand reflecting the negative impact, primarily in the supportive cancer care setting, of additional product label changes which occurred in the third quarter of 2008, and, to a lesser extent, loss of segment share. The decline in sales in the first quarter of 2009 was slightly offset by favorable changes in wholesaler inventories. International Aranesp sales decreased 6 percent to $334 million versus $356 million in the first quarter of 2008 due to the negative impact of changes in foreign exchange, which aggregated approximately $29 million, partially offset by an increase in demand. Excluding the impact of foreign exchange, worldwide product sales decreased 14 percent and international product sales increased 2 percent.

Sales of EPOGEN
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine news :

1. First biomarker discovered that predicts prostate cancer outcome
2. FDA Approves First Anti-Psychotic for Kids
3. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
4. First study examines newly-licensed RN work attitudes and intentions
5. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
8. High and mighty: first common height gene identified by researchers behind obesity gene finding
9. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
10. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
11. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... New Enterprise Associates, Inc. (NEA), a leading global ... its portfolio companies, Acclarent, Inc., has entered into ... Inc., a Johnson & Johnson company, in an ... estimated cash on hand at time of closing). ... and commercializing devices that address conditions affecting the ...
(Date:12/16/2009)... Blacks, other minorities might not gain full benefit from ... -- Human embryonic stem cell lines currently used for ... finds. , That could mean that non-whites will ... that research down the line, experts say. , Blacks ... most widely used stem cell lines studied showed any ...
(Date:12/16/2009)... WASHINGTON, Dec. 16 Losing has never felt ... knows maintaining his healthy new lifestyle means continuing to ... Drinking fat free milk is one healthy choice that ... a simple step everyone can take. Every glass of ... muscle, potassium to help maintain normal blood pressure, and ...
(Date:12/16/2009)... For wounded U.S. servicemen and women recovering at ... holidays can be a particularly difficult time. Wounded ... than ever on the healing power of connecting with ... got easier for Walter Reed patients as Verizon Wireless ... hundreds of minutes of holiday talk time for 2,500 ...
(Date:12/16/2009)... WASHINGTON, Dec. 16 As a result of ... a new peer reviewed cancer research program is included ... ,, This new cancer research program will research ... the breast, prostate, lung and ovarian cancer research programs ... Command. ,, The $15 million in funding ...
Breaking Medicine News(10 mins):Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:Most Stem Cells Used in Research Come From Whites 2Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3
... patients with chronic obstructive pulmonary disease (COPD) improves exercise ... unless they have resting hypoxemia, according to researchers in ... prescribed for those who do not meet criteria for ... of Medicine and Physical Therapy at West Park Healthcare ...
... pregnancy and breastfeeding may be putting their children at ... study funded by the Wellcome Trust and carried out ... that pregnant and breastfeeding women should not indulge in ... that they are "eating for two". , The study(1), ...
... is greater among kidney transplant patients and people with ... suggests the disease is associated with immune deficiency. ... South Wales in Sydney and colleagues compared the incidence ... with that of kidney transplant patients, who have suppressed ...
... measure apolipoprotein (apo) B: apo A-I ratio is not ... traditional lipid ratios that include total cholesterol and HDL-C, ... of JAMA. , Current risk-prediction instruments and guidelines for ... low-density lipoprotein cholesterol (LDL-C), total cholesterol, or both for ...
... can improve their understanding of the potential increased risk ... recent study conducted by researchers from The Childrens Hospital ... in New Haven, CT. , Like many radiology departments ... radiation exposure to children caused by increased usage of ...
Frederic Geissmann and colleagues find that Langerhans cell accumulation in Langerhans cell histiocytosis results from survival rather than uncontrolled proliferation, and is associated with the expan...
Other Medicine News:Health News:Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia 2Health News:Eating junk food whilst pregnant and breastfeeding may lead to obese offspring 2Health News:Use of certain lipid measures not more effective in predicting coronary heart disease 2Health News:Informational handout key to giving parents a better understanding of CT radiation risks 2
(Date:12/16/2009)... SALT LAKE CITY, Dec. 16 ... or the "Company"), a medical device company engaged ... breast ultrasound imaging system, announced today that Joe ... Board of Directors. ,, Board Chairman Ken ... to large medical devices companies, including GE OEC ...
(Date:12/16/2009)... Naurex Inc., a new clinical stage company developing ... based on its novel GFPA NMDA receptor modulators, ... I clinical trial of its lead compound GLYX-13 ... the study. GLYX-13, a glycine site functional ... receptor, is initially being developed as a therapy ...
(Date:12/16/2009)... ALTO, Calif., Dec. 16 The Boards ... Corporation are delighted to announce the merger of ... the field of RNAi (RNA interference). The ... have multiple RNAi discovery, development and delivery technologies, ... a broad portfolio of intellectual property. ,, ...
Breaking Medicine Technology:In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 2Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 4Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 5Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 6HMS Acquires IntegriGuard to Expand Program Integrity Capabilities 58521 1HMS Acquires IntegriGuard to Expand Program Integrity Capabilities 58521 2Patient Targeted Messaging for Emerging Multiple Sclerosis Agents Needs to Highlight Efficacy and Preservation of Quality of Life 5097 1Patient Targeted Messaging for Emerging Multiple Sclerosis Agents Needs to Highlight Efficacy and Preservation of Quality of Life 5097 2Patient Targeted Messaging for Emerging Multiple Sclerosis Agents Needs to Highlight Efficacy and Preservation of Quality of Life 5097 3Harris Corporation Demonstrates Secure Exchange of Public Health Information in Cloud Computing Environment 58517 1Harris Corporation Demonstrates Secure Exchange of Public Health Information in Cloud Computing Environment 58517 2Harris Corporation Demonstrates Secure Exchange of Public Health Information in Cloud Computing Environment 58517 3
... showed an improvement in median survival vs. ... parallel external controls -, ... today announced updated results from the Phase 2 study of,its investigational ... cytotoxic T lymphocyte (CTL) responses,and showed a positive survival trend in ...
... Nov. 1 In a move to improve,significantly ... leader in emergency medical information service, has joined,the ... and,support, to offer MedicAlert(R) + Safe Return(R). Currently, ... Alzheimer,s and almost 10 million,people caring for someone ...
Other Medicine Technology:IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients 2IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients 3IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients 4MedicAlert Foundation Joins The Alzheimer's Association to Offer MedicAlert(R) + Alzheimer's Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies 2MedicAlert Foundation Joins The Alzheimer's Association to Offer MedicAlert(R) + Alzheimer's Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: